BRANDI HYDE: Open Payments
NPI 1578243010 · PARAGOULD, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,964 in 165 payments from 25 companies in 2025. Trend: 2023 $579 · 2024 $2,342 · 2025 $2,964
Food & beverage: $2,964
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 18 | $342 |
| ABBVIE INC. | 23 | $338 |
| Neurelis, Inc. | 9 | $217 |
| Eisai Inc. | 13 | $215 |
| Neurocrine BioSciences, Inc. | 12 | $214 |
| SK Life Science, Inc. | 7 | $211 |
| PFIZER INC. | 18 | $197 |
| Amneal Pharmaceuticals LLC | 16 | $163 |
| UCB, Inc. | 7 | $140 |
| CSL Behring | 4 | $106 |
Products named: KESIMPTA, UBRELVY, VALTOCO, Leqembi, INGREZZA, NURTEC ODT, CREXONT, Hizentra.
Industry payments across AR — which companies pay providers there.
